AngioDynamics Stock Financials

ANGO Stock  USD 13.45  0.09  0.67%   
AngioDynamics Working Capital is quite stable at the moment as compared to the past year. The company's current value of Working Capital is estimated at 101 Million.
  
With this module, you can analyze AngioDynamics financials for your investing period. You should be able to track the changes in AngioDynamics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

AngioDynamics Most Recent Estimates

Diluted Eps
(1.02) 
EPS Estimate Current Year
(0.01) 
EPS Estimate Next Year
0.11
EPS Estimate Current Quarter
(0.01) 
Earnings Share
(1.02) 
Understanding current and past AngioDynamics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of AngioDynamics' financial statements are interrelated, with each one affecting the others. For example, an increase in AngioDynamics' assets may result in an increase in income on the income statement.

Revenues

276 Million

The financial analysis of AngioDynamics is a critical element in measuring its lifeblood. The essential information of the day-to-day investment outlook for AngioDynamics includes many different criteria found on its balance sheet. For example, investors should never minimize AngioDynamics' ability to pay suppliers or employees on time, making sure interest payments are not accumulating or correctly timing where and how to re-invest extra cash. Any individual investor needs to monitor AngioDynamics' cash flow, debt, and profitability to effectively and accurately make more informed decisions on whether to invest in AngioDynamics.

AngioDynamics Cash

Chance Of Financial Distress
Less than 1
AngioDynamics has less than 1 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for AngioDynamics stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in AngioDynamics' official financial statements usually reflect AngioDynamics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of AngioDynamics. For example, before you start analyzing numbers published by AngioDynamics accountants, it's critical to develop an understanding of what AngioDynamics' liquidity, profitability, and earnings quality are in the context of the Health Care Equipment & Supplies space in which it operates.
Please note, the presentation of AngioDynamics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AngioDynamics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in AngioDynamics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of AngioDynamics. Please utilize our Beneish M Score to check the likelihood of AngioDynamics' management to manipulate its earnings.

AngioDynamics Company Summary

AngioDynamics competes with Games Workshop, Bar Harbor, Universal Insurance, Virginia National, and Evolution Gaming. AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access and for use in oncology and surgical settings in the United States and internationally. The company was founded in 1988 and is headquartered in Latham, New York. Angiodynamics operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 760 people.
Specialization
Health Care, Health Care Equipment & Services
InstrumentUSA Stock View All
ExchangeNASDAQ Exchange
CIK Number0001275187
ISINUS03475V1017
RegionNorth America
Business Address14 Plaza Drive,
SectorHealth Care Equipment & Supplies
IndustryHealth Care
BenchmarkNYSE Composite
Websitewww.angiodynamics.com
Phone518 795 1400
CurrencyUSD - US Dollar
You should never invest in AngioDynamics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of AngioDynamics Stock, because this is throwing your money away. Analyzing the key information contained in AngioDynamics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

AngioDynamics Key Financial Ratios

Generally speaking, AngioDynamics' financial ratios allow both analysts and investors to convert raw data from AngioDynamics' financial statements into concise, actionable information that can be used to evaluate the performance of AngioDynamics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that AngioDynamics reports annually and quarterly.

AngioDynamics Key Balance Sheet Accounts

201820192020202120222023 (projected)
Inventories40.07 M59.91 M48.61 M51.39 M46.25 M45.57 M
Receivables43.58 M34.17 M35.41 M52.3 M47.07 M43.52 M
Accounts Payable22.83 M19.1 M19.63 M28.05 M25.24 M22.12 M
Total Assets836.44 M594.21 M561.44 M552.75 M497.48 M541.47 M
Current Assets315.29 M152.91 M140.88 M143.34 M129.01 M139 M
Assets Non Current521.15 M441.3 M420.56 M409.41 M368.47 M421.5 M
Cash and Equivalents227.64 M54.44 M48.16 M28.82 M25.94 M36.25 M
Total Debt131.91 M40 M20 M25 M22.5 M23.09 M
Debt Non Current124.41 M40 M20 M25 M22.5 M23.09 M
Shareholders Equity614.82 M454.87 M439.46 M424.49 M382.04 M409.29 M
Inventory40.07 M59.91 M48.61 M51.39 M46.25 M46.88 M
Total Liabilities221.62 M139.34 M121.98 M128.26 M115.44 M132.18 M
Current Liabilities73.3 M51.45 M57.58 M74.32 M66.89 M59.69 M
Tax Liabilities14.54 M24.06 M19.95 M16.04 M18.44 M18.9 M

AngioDynamics Key Income Statement Accounts

An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket. The other reason investors look at the income statement is to determine what AngioDynamics' earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
201820192020202120222023 (projected)
Direct Expenses114.63 M113.89 M134.22 M150.49 M135.44 M130.76 M
Consolidated Income61.34 M(166.79 M)(31.55 M)(26.55 M)(23.89 M)(25.78 M)
Cost of Revenue114.63 M113.89 M134.22 M150.49 M135.44 M131.05 M
Gross Profit156 M150.27 M156.79 M165.73 M149.16 M145.13 M
Interest Expense5.1 M907 K861 K688 K619.2 K635.5 K
Net Income61.34 M(166.79 M)(31.55 M)(26.55 M)(30.53 M)(31.33 M)
Operating Expenses172.38 M329.03 M191.89 M193.78 M222.85 M224.47 M
Operating Income(9.4 M)(167.1 M)(35.28 M)(28.47 M)(32.74 M)(33.6 M)
Revenues270.63 M264.16 M291.01 M316.22 M284.6 M276 M
Income Tax Expense(3.56 M)(1.35 M)(4.5 M)(3.4 M)(3.06 M)(3.14 M)

AngioDynamics Key Cash Accounts

Cash flow analysis captures how much money flows into and out of AngioDynamics. It measures of how well AngioDynamics is doing because it can show the actual money that comes into and out of the company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money AngioDynamics brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money AngioDynamics had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what AngioDynamics has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
201820192020202120222023 (projected)
Capital Expenditure(3.12 M)(7.24 M)(13.71 M)(15.71 M)(14.14 M)(14.51 M)
Depreciation Amortization and Accretion25.88 M25.88 M28.37 M31.79 M36.56 M34.4 M
Net Cash Flow or Change in Cash and Cash Equivalents153.54 M(173.21 M)(6.27 M)(19.34 M)(17.4 M)(17.86 M)
Issuance Purchase of Equity Shares2.03 M(759 K)3.01 M2.68 M2.41 M2.04 M
Issuance Repayment of Debt Securities40 M(92.5 M)(20 M)5 M4.5 M4.86 M
Net Cash Flow from Financing33.93 M(95.24 M)(16.99 M)7.68 M8.84 M9.53 M
Net Cash Flow from Investing82.55 M(63.34 M)(13.71 M)(19.31 M)(17.38 M)(18.75 M)
Net Cash Flow from Operations37.44 M(14.55 M)24.09 M(7.19 M)(8.27 M)(8.49 M)
Share Based Compensation9.25 M7.59 M8.62 M10.69 M12.3 M10.24 M

AngioDynamics Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining AngioDynamics's current stock value. Our valuation model uses many indicators to compare AngioDynamics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across AngioDynamics competition to find correlations between indicators driving AngioDynamics's intrinsic value. More Info.
AngioDynamics is number one stock in book value per share category among related companies. It is number one stock in current liabilities category among related companies creating about  6,461,412  of Current Liabilities per Book Value Per Share. AngioDynamics Book Value per Share is quite stable at the moment as compared to the past year. The company's current value of Book Value per Share is estimated at 11.27. Comparative valuation analysis is a catch-all model that can be used if you cannot value AngioDynamics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for AngioDynamics' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the AngioDynamics' earnings, one of the primary drivers of an investment's value.

AngioDynamics Systematic Risk

AngioDynamics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. AngioDynamics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was two with a total number of output elements of fifty-nine. The Beta measures systematic risk based on how returns on AngioDynamics correlated with the market. If Beta is less than 0 AngioDynamics generally moves in the opposite direction as compared to the market. If AngioDynamics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one AngioDynamics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of AngioDynamics is generally in the same direction as the market. If Beta > 1 AngioDynamics moves generally in the same direction as, but more than the movement of the benchmark.
.

About AngioDynamics Financials

What exactly are AngioDynamics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include AngioDynamics' income statement, its balance sheet, and the statement of cash flows. Potential AngioDynamics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although AngioDynamics investors may use each financial statement separately, they are all related. The changes in AngioDynamics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on AngioDynamics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

Steps to analyze AngioDynamics Financials for Investing

There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as AngioDynamics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of AngioDynamics has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.
In summary, you can determine if AngioDynamics' financials are consistent with your investment objective using the following steps:
  • Review AngioDynamics' balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
  • Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
  • Study the cash flow inflows and outflows to understand AngioDynamics' liquidity and solvency.
  • Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
  • Compare AngioDynamics' financials to those of its peers to see how it stacks up and identify any potential red flags.
  • Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if AngioDynamics' stock is overvalued or undervalued.
Remember, these are just guidelines and should not be the only basis for investment decisions. It is always important to conduct additional research and seek professional advice.

AngioDynamics Thematic Clasifications

AngioDynamics is part of Cancer Fighters investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases
Cancer Fighters Idea
Cancer FightersView
This theme covers Public companies from health care and pharmaceutical sectors that are focused on fighting cancer. Biotech and medical diagnostic companies that work on researching drugs or manufacturing of medical and therapeutics equipment that is directly related to the research, treatment, and detection of cancer or cancer related diseases. Get More Thematic Ideas

AngioDynamics February 2, 2023 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of AngioDynamics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of AngioDynamics. We use our internally-developed statistical techniques to arrive at the intrinsic value of AngioDynamics based on widely used predictive technical indicators. In general, we focus on analyzing AngioDynamics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build AngioDynamics's daily price indicators and compare them against related drivers.
Please continue to Trending Equities. Note that the AngioDynamics information on this page should be used as a complementary analysis to other AngioDynamics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Watchlist Optimization module to optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm.

Complementary Tools for AngioDynamics Stock analysis

When running AngioDynamics price analysis, check to measure AngioDynamics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AngioDynamics is operating at the current time. Most of AngioDynamics' value examination focuses on studying past and present price action to predict the probability of AngioDynamics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move AngioDynamics' price. Additionally, you may evaluate how the addition of AngioDynamics to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Money Managers
Screen money managers from public funds and ETFs managed around the world
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Is AngioDynamics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AngioDynamics. If investors know AngioDynamics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AngioDynamics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
522.8 M
Quarterly Revenue Growth
0.091
Return On Assets
(0.0247) 
Return On Equity
(0.08) 
The market value of AngioDynamics is measured differently than its book value, which is the value of AngioDynamics that is recorded on the company's balance sheet. Investors also form their own opinion of AngioDynamics' value that differs from its market value or its book value, called intrinsic value, which is AngioDynamics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AngioDynamics' market value can be influenced by many factors that don't directly affect AngioDynamics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AngioDynamics' value and its price as these two are different measures arrived at by different means. Investors typically determine AngioDynamics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AngioDynamics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.